The Differences Between the Obama and Bush White House: A Look Ahead
This article was originally published in RPM Report
Former HHS general counsel Dan Meron, now a partner at Latham & Watkins, was asked to make predictions on how the Obama Administration would differ from the Bush Administration in a recent speech to the annual meeting of the Food, Drug and Cosmetic Law Section of the New York Bar Association. His remarks were edited for continuity.
You may also be interested in...
The withdrawal of Tom Daschle from consideration as HHS Secretary means there won't be a single focus for health care policy during the upcoming health care reform debate. Can two powerful Democratic legislators and the Obama budget team fill the void?
As the presidential race heats up, health care executives say they have many reasons to be excited–and nervous. Boston Consulting Group reviews an industry-wide survey on the implications of the candidates’ health care proposals for the pharma and device industries.
Should a Democrat take the White House next January, top pharmaceutical executives expect a serious push for health care reform. The prospect of a health care reform debate triggers the specter of a single-payor, government-run system with price controls. But Democrats are singing a surprisingly soothing tune.